Clarity Pharmaceuticals Ltd. has expanded its pipeline with a new fibroblast activation protein (FAP)-targeted radiopharmaceutical for the diagnosis and treatment of cancer. Clarity’s targeted copper theranostic targeting FAP was developed by combining an industry-leading FAP inhibitor with proprietary SAR chelator technology, which enables the use of copper-64 (64Cu) for imaging and copper-67 (67Cu) for the targeted treatment of various cancers.